文献速递瓣膜外科

2005例老年患者常规主动脉瓣置换术:32年经验

Conventional aortic valve replacement in 2005 elderly patients: a 32-year experience.
PubMed 文献 · Eur J Cardiothorac Surg · 2018-01-01

该研究回顾了1978至2011年间在本机构因主动脉瓣狭窄接受常规主动脉瓣置换术的2005例80岁及以上患者,评估其长期结果。结果显示孤立手术近10年早期死亡率为5.5%,中位生存7.1年,90%的晚期存活者报告功能改善,结论认为不应仅因高龄而拒绝手术。

要点

  • 80岁及以上主动脉瓣狭窄患者接受常规主动脉瓣置换术的长期生存良好,中位生存7.1年。
  • 孤立主动脉瓣置换术近10年早期死亡率为5.5%,晚期存活者中90%报告功能改善。
  • 合并症、肾功能衰竭、晚期心脏病、房颤和心室功能受损是晚期死亡的危险因素。

核心结论

  • 主动脉瓣置换术对所有年龄组治疗主动脉瓣狭窄均有效,不应仅因高龄而拒绝手术,因为常规主动脉瓣置换术提供极好的生活质量和恢复预期寿命。
  • 经皮瓣膜植入应考虑用于不可手术或高风险患者,但迄今为止开放心脏手术仍是大多数主动脉瓣狭窄患者的首选治疗。

研究设计与样本

  • 回顾性队列研究,纳入1978年至2011年间在本机构因主动脉瓣狭窄接受主动脉瓣置换术的2005例80岁及以上患者。
  • 其中1009例(50%)患者合并心外合并症,650例(32%)患者有冠状动脉病变。
  • 1515例(76%)患者仅接受瓣膜置换术,396例(19%)患者同期接受冠状动脉旁路移植术。

主要发现

  • 孤立主动脉瓣置换术近10年早期死亡率为5.5%。
  • 长期随访完整率99.5%(9例失访),总计8849患者年。
  • 晚期随访中901例患者死亡,中位生存7.1年,7例成为百岁老人。
  • 除高龄外,主要晚期死亡原因包括心血管原因(20.5%)、神经功能缺损(10.2%)和癌症(10.2%)。
  • 2年、5年和10年生存率分别为83%、62.5%和25%。

关键数值与推荐

  • 单变量和多变量分析确定晚期死亡的危险因素为男性、合并症、肾功能衰竭、晚期心脏病、心房颤动和心室功能受损。
  • 冠状动脉病变、合并心脏手术和小直径人工瓣膜(19或21 mm)未影响长期生存。

临床怎么用

  • 作者认为主动脉瓣置换术对所有年龄组治疗主动脉瓣狭窄均有效,不应仅因高龄而拒绝手术。
  • 作者认为经皮瓣膜植入应考虑用于不可手术或高风险患者,但开放心脏手术仍是大多数主动脉瓣狭窄患者的首选治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Considering the good immediate results reported for transcatheter aortic valve implantation in high-risk patients, the role of conventional aortic valve replacement (AVR) is being questioned, especially in elderly patients. The aim of this study was to evaluate our long-term results of conventional AVR in octogenarians. METHODS: A total of 2005 patients aged ≥80 years underwent AVR for aortic stenosis in our institution between 1978 and 2011. Of these, 1009 (50%) patients had an associated extracardiac comorbidity and 650 (32%) patients had coronary lesions. Valve replacement was the sole procedure in 1515 (76%) patients, and 396 (19%) patients had concomitant coronary artery bypass grafting. Data were collected at the time of surgery in our database, and regularly updated by mailed questionnaires and telephone contact. RESULTS: Early mortality of isolated AVR was 5.5% for the last 10 years of the series. Significant risk factors were chronic obstructive pulmonary disease, chronic renal failure, advanced cardiac disease [left or right ventricular failure, New York Heart Association (NYHA) Class IV and atrial fibrillation] and coronary disease. Long-term follow-up was 99.5% complete (9 patients lost to follow-up), totalling 8849 patient-years. Nine hundred and one patients died at late follow-up with a median survival of 7.1 years, with 7 patients becoming centenarian. Apart from older age, main late causes of death were cardiovascular (20.5%), neurological deficit (10.2%) and cancer (10.2%). Actuarial survival was 83%, 62.5% and 25% at 2, 5 and 10 years, respectively. This survival compares favourably with that of a French-matched population. Above all, 90% of late survivors reported functional improvement. Univariable and multivariable analysis identified risk factors of late death as male gender, associated comorbidity, renal failure, advanced cardiac disease, atrial fibrillation and impaired ventricular function. Coronary lesions, associated cardiac surgery and small diameter prostheses (19 or 21 mm) did not impair long-term survival. CONCLUSIONS: AVR is effective for all age groups to treat aortic stenosis. Elderly people should not be denied surgery only because of their old age as conventional AVR provides an excellent quality of life and restores life expectancy. Percutaneous valve implantation is to be considered, in cases of non-operable or high-risk patients. However, to date, open-heart surgery remains the treatment of choice for aortic stenosis for the majority of patients.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Langanay T, Rouzé S, Tomasi J, et al. Conventional aortic valve replacement in 2005 elderly patients: a 32-year experience. Eur J Cardiothorac Surg. 2018. PMID: 29566140. doi:10.1093/ejcts/ezy072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。